Changes in magnetic resonance mammography due to hormone replacement therapy

[1]  P. Delmas.  Hormone replacement therapy in the prevention and treatment of osteoporosis , 2005, Osteoporosis International.

[2]  K. Brubaker.  Perspectives on the women's health initiative trial of hormone replacement therapy. , 2003, Obstetrics and gynecology.

[3]  W. Kaiser,et al.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.

[4]  P. Wingo,et al.  Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma , 2002, Cancer.

[5]  Celine M Vachon,et al.  Case-control study of increased mammographic breast density response to hormone replacement therapy. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  U. Gembruch,et al.  Strong impact of estrogen environment on Doppler variables used for differentiation between benign and malignant breast lesions , 2002, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[7]  H. Degani,et al.  Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. , 2002, Cancer research.

[8]  E. Banks.  Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review , 2001, Journal of medical screening.

[9]  W E Reddick,et al.  MR imaging of tumor microcirculation: Promise for the new millenium , 1999, Journal of magnetic resonance imaging : JMRI.

[10]  G. Erbaş,et al.  Mammographic and ultrasonographic study of changes in the breast related to HRT , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[11]  J R Reichenbach,et al.  Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. , 1999, Journal of computer assisted tomography.

[12]  J. Litherland,et al.  The effect of hormone replacement therapy on the sensitivity of screening mammograms. , 1999, Clinical radiology.

[13]  N Roberts,et al.  Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. , 1999, The British journal of radiology.

[14]  E. Merkle,et al.  MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease , 1999, European Radiology.

[15]  M. Gibaldi.  Prevention and Treatment of Osteoporosis: Does the Future Belong to Hormone Replacement Therapy? , 1997, Journal of clinical pharmacology.

[16]  C. Herman,et al.  Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. , 1997, Journal of the National Cancer Institute.

[17]  L. Holmberg,et al.  Hormone replacement therapy and the risk of breast cancer. Nested case‐control study in a cohort of Swedish women attending mammography screening , 1997, International journal of cancer.

[18]  C. Claussen,et al.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. , 1997, Radiology.

[19]  G Lutterbey,et al.  Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.

[20]  A Heinig,et al.  Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. , 1997, European journal of radiology.

[21]  D B Plewes,et al.  Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 t , 1995, Journal of magnetic resonance imaging : JMRI.

[22]  M. Pike,et al.  Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. , 1994, Journal of the National Cancer Institute.

[23]  K. Zedeler,et al.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[24]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[25]  K. Zedeler,et al.  Lobular Carcinoma In Situ of the Female Breast , 1992 .

[26]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[27]  J. Prior.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[28]  L. Hayman,et al.  Correspondence , 1992, Neuroradiology.

[29]  P A Fowler,et al.  Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging , 1990, British journal of obstetrics and gynaecology.

[30]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[31]  S. E. el Yousef,et al.  Transverse Relaxation Time Values in MR Imaging of Normal Breast During Menstrual Cycle , 1986, Journal of computer assisted tomography.

[32]  T. Nelson,et al.  Menstrual Variation of Normal Breast NMR Relaxation Parameters , 1985, Journal of computer assisted tomography.